Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 1/2019

01-01-2019 | Original Article

The Significance of Long Non-coding RNA HULC in Predicting Prognosis and Metastasis of Cancers: a Meta-Analysis

Authors: Yangyang Ding, Cheng Sun, Jingrong Li, Linhui Hu, Manman Li, Jun Liu, Lianfang Pu, Shudao Xiong

Published in: Pathology & Oncology Research | Issue 1/2019

Login to get access

Abstract

Long non-coding RNAs (lncRNAs) have been demonstrated that they not only play important roles in tumorgenicity but also associate with cancer prognosis. Recently, highly up-regulated in liver cancer (HULC) is abnormally expressed in liver cancer and other cancers, and participated in cancers progression; however, it is unclear whether its expression is associated with prognosis. Here, we performed a meta-analysis and systematic review to evaluate the prognostic value and metastasis of HULC in various cancer patients. The meta-analysis was performed using a systematic search of PubMed, Web of Science, ScienceDirect and Wiley Online Library database to eligible studies. The pooled hazard ratios (HRs) with a 95% confidence interval (95% CI) were calculated to assess its prognosis and metastasis in human cancer. A total of 1134 patients from 11 studies were included. The results indicated that overexpression of HULC was associated with poor overall survival (OS) (HR = 1.89, 95% CI: 1.32–2.47). Furthermore, subgroup analysis showed that cancer type (digestive system cancer or non-digestive system cancers) and sample size (more or less than 100) significantly associated between HULC and OS. In addition, overexpression of HULC expression was significantly associated with metastasis in cancers (HR = 2.67, 95% CI: 0.94–4.39). The meta-analysis indicated that lncRNA HULC could serve as a new molecular marker for cancer prognosis and metastasis.
Literature
1.
Wu S, Powers S, Zhu W, Hannun YA (2016) Substantial contribution of extrinsic risk factors to cancer development. Nature 529:43–47CrossRefPubMed
2.
Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrozek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD (2014) Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A 111:18679–18684CrossRefPubMedPubMedCentral
3.
Kim SH, Lee HW, Go SI, Lee SI, Lee GW (2016) Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. Oncotarget 7:36198–36206PubMedPubMedCentral
4.
Chan JC, Chan DL, Diakos CI, Engel A, Pavlakis N, Gill A, Clarke SJ (2016) The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg 265:539–546
5.
6.
7.
8.
Ylipaa A, Kivinummi K, Kohvakka A, Annala M, Latonen L, Scaravilli M, Kartasalo K, Leppanen SP, Karakurt S, Seppala J, Yli-Harja O, Tammela TL, Zhang W, Visakorpi T, Nykter M (2015) Transcriptome sequencing reveals PCAT5 as a novel ERG-regulated long noncoding RNA in prostate cancer. Cancer Res 75:4026–4031CrossRefPubMed
9.
Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K (2007) Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132:330–342CrossRefPubMed
10.
Sun X-H, Yang L-B, Geng X-L, Wang R, Zhang Z-C (2015) Increased expression of IncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma. Int J Clin Exp Pathol 8:2994–3000PubMedPubMedCentral
11.
Wang YF, Zhang S, Li XQ, Wang Y (2016) Expression of lncRNA HULC in cervical cancer and its correlation with tumor progression and patient survival. Eur Rev Med Pharmacol Sci 20:3987–3991PubMed
12.
Yang XJ, Huang CQ, Peng CW, Hou JX, Liu JY (2016) Long noncoding RNA HULC promotes colorectal carcinoma progression through epigenetically repressing NKD2 expression. Gene 592:172–178CrossRefPubMed
13.
Shi F, Xiao F, Ding P, Qin H, Huang R, Long Noncoding RNA (2016) Highly up-regulated in liver cancer predicts unfavorable outcome and regulates metastasis by MMPs in triple-negative breast cancer. Arch Med Res 47:446–453CrossRefPubMed
14.
Peng W, Wu J, Feng J (2016) Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma. Biomed Pharmacother 79:188–193CrossRefPubMed
15.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16CrossRefPubMedPubMedCentral
16.
Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289CrossRefPubMed
17.
Fang K, Liu P, Dong S, Guo Y, Cui X, Zhu X, Li X, Jiang L, Liu T, Magnetofection YW (2016) Based on superparamagnetic iron oxide nanoparticle-mediated low lncRNA HOTAIR expression decreases the proliferation and invasion of glioma stem cells. Int J Oncol 49:509–518CrossRefPubMedPubMedCentral
18.
Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zornig M, MacLeod AR, Spector DL, Diederichs S (2013) The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 73:1180–1189CrossRefPubMed
19.
Du Y, Kong G, You X, Zhang S, Zhang T, Gao Y, Ye L, Zhang X (2012) Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem 287:26302–26311CrossRefPubMedPubMedCentral
20.
Zhang Y, Li Z, Zhang Y, Zhong Q, Chen Q, Zhang L (2015) Molecular mechanism of HEIH and HULC in the proliferation and invasion of hepatoma cells. Int J Clin Exp Med 8:12956–12962PubMedPubMedCentral
21.
Ma Y, Huang D, Yang F, Tian M, Wang Y, Shen D, Wang Q, Chen Q, Zhang L, Long Noncoding RNA (2016) Highly upregulated in liver cancer regulates the tumor necrosis factor-alpha-induced apoptosis in human vascular endothelial cells. DNA Cell Biol 35:296–300CrossRefPubMed
22.
Lu Z, Xiao Z, Liu F, Cui M, Li W, Yang Z, Li J, Ye L, Zhang X (2016) Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1). Oncotarget 7:241–254PubMed
23.
Cui M, Xiao Z, Wang Y, Zheng M, Song T, Cai X, Sun B, Ye L, Zhang X (2015) Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res 75:846–857CrossRefPubMed
24.
Maciel Uzan VR, Lengert AvH, Boldrini E, Penna V, Scapulatempo-Neto C, Scrideli CA, de Moraes Filho AP, Bezerra Cavalcante CE, de Oliveira CZ, Lopes LF, Vidal DO (2016) High expression of HULC is associated with poor prognosis in osteosarcoma patients. PLoS One 11:e0156774CrossRef
25.
Li D, Liu X, Zhou J, Hu J, Zhang D, Liu J, Qiao Y, Zhan Q, LncRNA HULC (2016) Modulates the phosphorylation of YB-1 through serving as a scaffold of ERK and YB-1 to enhance hepatocarcinogenesis. Hepatology 65:1612–1627CrossRef
26.
Yu X, Zheng H, Chan MT, Wu WK (2016) HULC: an oncogenic long non-coding RNA in human cancer. J Cell Mol Med 21:410–417
27.
Yang Z, Lu Y, Xu Q, Tang B, Park CK, Chen X (2015) HULC and H19 played different roles in overall and disease-free survival from hepatocellular carcinoma after curative hepatectomy: a preliminary analysis from gene expression omnibus. Dis Markers 2015:191029PubMedPubMedCentral
28.
Li S-P, Xu H-X, Yu Y, He J-D, Wang Z, Xu Y-J, Wang C-Y, Zhang H-M, Zhang R-X, Zhang J-J, Yao Z, Shen Z-Y, LncRNA HULC (2016) Enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget 7:42431–42446PubMedPubMedCentral
29.
Yan H, Tian R, Zhang M, Wu J, Ding M, He J (2017) High expression of long noncoding RNA HULC is a poor predictor of prognosis and regulates cell proliferation in glioma. Onco Targets Ther 10:113–120CrossRefPubMed
30.
Jin C, Shi W, Wang F, Shen X, Qi J, Cong H, Yuan J, Shi L, Zhu B, Luo X, Zhang Y, Long SJ (2016) Non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer. Oncotarget 7:51763–51772PubMedPubMedCentral
31.
Peng W, Gao W, Feng J (2014) Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol 31:346CrossRefPubMed
Metadata
Title
The Significance of Long Non-coding RNA HULC in Predicting Prognosis and Metastasis of Cancers: a Meta-Analysis
Authors
Yangyang Ding
Cheng Sun
Jingrong Li
Linhui Hu
Manman Li
Jun Liu
Lianfang Pu
Shudao Xiong
Publication date
01-01-2019
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0351-y

Other articles of this Issue 1/2019

Pathology & Oncology Research 1/2019 Go to the issue

Original Article

Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review

Original Article

Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results

Original Article

Expression of Glut-1 in Malignant Melanoma and Melanocytic Nevi: an Immunohistochemical Study of 400 Cases

Original Article

Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma

Original Article

In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid

Original Article

Pim-2 Cooperates with Downstream Factor XIAP to Inhibit Apoptosis and Intensify Malignant Grade in Prostate Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits